The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases, reviewing issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
EgorinM.J., Van EchoD.A., TippingS.J.Pharmacokinetics and dosage reduction in cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.Cancer Res.1984; 44: 5432–8.
2.
NewellD.R., SiddikZ.H., GumbrellL.A.Plasma free platinum concentrations in patients treated with high dose carboplatin.Eur J Cancer Clin Oncol.1987; 23: 1399–1405.
3.
HarlandS.J., GumbrellL.A., HorwichA.Carboplatin dose in combination chemotherapy for testicular cancer.Eur J Cancer.1991; 27: 691–5.
4.
HorwichA., DearnaleyD.F., NicholsJ.Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good prognosis metastatic testicular non-seminomatous germ cell tumors.J Clin Oncol.1991; 9: 62–9.
5.
JodrellD.I., EgorinM.J., CanettaR.M.Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.J Clin Oncol.1998; 10: 520–8.
6.
JonesA., WiltshawE., HarperP.A randomized study of high vs conventional dose carboplatin for previously untreated ovarian cancer.Br J Cancer.1992; 65(suppl 16): 15.
7.
van der VijghW.J.F.Clinical pharmacokinetics of carboplatin.Clinical Pharmacokinet.1991; 21: 242–61.
8.
CalvertA.H., NewellD.R., GumbrellL.A.Carboplatin dosage: Prospective evaluation of a simple formula based on renal function.J Clin Oncol.1989; 7: 1748–56.
9.
WaddellJ.A., SolimandoD.A.Verifying carboplatin dose calculations with the Calvert formula and the modified Calvert formula in adult patients.Hosp Pharm.35(9): 914–22.
10.
PinkertonC.R., BroadbentV., HorwichA.“JEB”: A carboplatin based regimen for malignant germ cell tumours in children.Br J Cancer.1990; 62(2): 257–62.
11.
MarinaN.M., RodmanJ., ShemaS.J.Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.J Clin Oncol.1993; 11(3): 554–60.
12.
MarinaN.M., RodmanJ.H., MurryD.J.Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.J Natl Cancer Inst.1994; 86(7): 544–8.
13.
TondaM.E., HeidemanR.L., PetrosW.P.Carboplatin pharmacokinetics in young children with brain tumors.Cancer Chemother Pharmacol.1996; 38(5): 395–400.
14.
MurryD.J., SandlundJ.T., StricklinL.M.Pharmacokinetics and acute renal effects of continuously infused carboplatin.Clin Pharmacol Ther.1993; 54(4): 374–80.
15.
NewellD.R., PearsonA.D., BalmannoK.Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.J Clin Oncol.1993; 11(12): 2314–23.
16.
CalvertA.H., NewellD.R., BalmannoK.Pharmacokinetics of carboplatin in children and the development of a paediatric dose equation. In: HowellS.B. (ed.). Platinum and Other Coordination Compounds in Cancer Chemotherapy.New York, NY: Plenum; 1991, 335–343.
17.
ThomasH., BoddyA.V., EnglishM.W.Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.J Clin Oncol.2000; 18(21): 3614–21.
18.
MannJr, RaafatF., RobinsonK.UKCCSG's germ cell tumour (GCT) studies: Improving outcome for children with malignant extracranial nongonadal tumours—carboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens. United Kingdom Children's Cancer Study Group.Med Pediatr Oncol.1998; 30(4): 217–27.
19.
RahnK.H., HeidenreichS., BrucknerD.How to assess glomerular function and damage in humans.J Hypertens.1999; 17: 309–17.
20.
WrightJ.G., BoddyA.V., HighleyM.Estimation of glomerular filtration rate in cancer patients.Br J Cancer.2001; 84(4): 452–9.
21.
CockcroftD.W., GaultM.H.Prediction of creatinine clearance from serum creatinine.Nephron.1976; 16(1): 31–41.
